Healthcare provider profile · identity verified

Omer Khalil, MD

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · LITTLE ROCK, AR · NPI 1467671792

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Omer Khalil, MD received $13.56 in general payments during 2025 across 1 reported records.

PFIZER INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ibrance by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Orgovyx by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Xtandi by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$13.56

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
PFIZER INC.	Unresolved — no canonical attribution shown	$13.56	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$13.56	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ADCETRIS Normalized: adcetris	Biological	PFIZER INC.	$13.56	1	2025
Source payment records 2025-04-29 · PFIZER INC. · $13.56 · Open Payments source
ELREXFIO Normalized: elrexfio	Drug	PFIZER INC.	$13.56	1	2025
Source payment records 2025-04-29 · PFIZER INC. · $13.56 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	160	32
PFIZER INC. Exact reporting entity; no affiliate inference	2025	IBRANCE open payments reported associated product	CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164	Ibrance · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ORGOVYX open payments reported associated product	CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230	Orgovyx · 2024 Exact normalized brand match · 1 Part D row	40	suppressed by CMS
PFIZER INC. Exact reporting entity; no affiliate inference	2025	XTANDI open payments reported associated product	CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230	Xtandi · 2024 Exact normalized brand match · 1 Part D row	37	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	359	78
Pantoprazole Sodium	Pantoprazole Sodium	338	75
Oxycodone Hcl	Oxycodone Hcl	282	31
Amlodipine Besylate	Amlodipine Besylate	184	47
Prednisone	Prednisone	174	54
Potassium Chloride	Potassium Chloride	170	42
Eliquis	Apixaban	160	32
Lorazepam	Lorazepam	156	28
Gabapentin	Gabapentin	155	41
Procrit	Epoetin Alfa	147	32
Ondansetron Hcl	Ondansetron Hcl	143	71
Zolpidem Tartrate	Zolpidem Tartrate	133	24
Anastrozole	Anastrozole	131	24
Folic Acid	Folic Acid	116	25
Letrozole	Letrozole	113	19
Promethazine Hcl	Promethazine Hcl	106	46
Xarelto	Rivaroxaban	104	16
Alprazolam	Alprazolam	96	14
Mirtazapine	Mirtazapine	96	23
Mvasi	Bevacizumab-Awwb	95	11
Jakafi	Ruxolitinib Phosphate	93	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	86	15
Metoprolol Succinate	Metoprolol Succinate	83	15
Tramadol Hcl	Tramadol Hcl	80	21
Warfarin Sodium	Warfarin Sodium	74	11
Darzalex	Daratumumab	68	suppressed
Dexamethasone	Dexamethasone	67	26
Escitalopram Oxalate	Escitalopram Oxalate	63	17
Clopidogrel	Clopidogrel Bisulfate	59	11
Famotidine	Famotidine	59	suppressed
Hydroxyurea	Hydroxyurea	57	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	56	14
Pregabalin	Pregabalin	56	16
Furosemide	Furosemide	54	22
Memantine Hcl	Memantine Hcl	54	12
Duloxetine Hcl	Duloxetine Hcl	51	suppressed
Ropinirole Hcl	Ropinirole Hcl	51	suppressed
Sertraline Hcl	Sertraline Hcl	51	13
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	50	18
Levothyroxine Sodium	Levothyroxine Sodium	50	suppressed
Megestrol Acetate	Megestrol Acetate	48	27
Tamsulosin Hcl	Tamsulosin Hcl	47	suppressed
Ondansetron Odt	Ondansetron	45	16
Hydrocortisone	Hydrocortisone	44	suppressed
Lenalidomide	Lenalidomide	43	suppressed
Fluconazole	Fluconazole	42	21
Fulvestrant	Fulvestrant	40	suppressed
Orgovyx	Relugolix	40	suppressed
Testosterone Cypionate	Testosterone Cypionate	40	suppressed
Xgeva	Denosumab	40	suppressed
Klor-Con M20	Potassium Chloride	39	12
Lisinopril	Lisinopril	38	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	37	11
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	37	suppressed
Tamoxifen Citrate	Tamoxifen Citrate	37	suppressed
Xtandi	Enzalutamide	37	suppressed
Diazepam	Diazepam	35	suppressed
Nifedipine Er	Nifedipine	35	suppressed
Venclexta	Venetoclax	35	suppressed
Deferasirox	Deferasirox	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Levofloxacin	Levofloxacin	34	30
Metformin Hcl	Metformin Hcl	34	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	22
Keytruda	Pembrolizumab	33	suppressed
Omeprazole	Omeprazole	33	11
Diclofenac Sodium	Diclofenac Sodium	32	suppressed
Eszopiclone	Eszopiclone	32	suppressed
Kisqali	Ribociclib Succinate	32	suppressed
Atorvastatin Calcium	Atorvastatin Calcium	31	suppressed
Baclofen	Baclofen	31	11
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	31	suppressed
Glipizide	Glipizide	31	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	31	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	31	14
Meloxicam	Meloxicam	29	suppressed
Neulasta Onpro	Pegfilgrastim	29	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	29	suppressed
Linzess	Linaclotide	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Trazimera	Trastuzumab-Qyyp	28	suppressed
Cephalexin	Cephalexin	27	suppressed
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	27	suppressed
Glipizide Er	Glipizide	27	suppressed
Morphine Sulfate Er	Morphine Sulfate	27	suppressed
Clonazepam	Clonazepam	26	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	26	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	26	suppressed
Primidone	Primidone	26	suppressed
Bupropion Xl	Bupropion Hcl	25	suppressed
Finasteride	Finasteride	24	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	24	19
Allopurinol	Allopurinol	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Doptelet	Avatrombopag Maleate	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Jardiance	Empagliflozin	23	suppressed
Midodrine Hcl	Midodrine Hcl	23	suppressed
Sucralfate	Sucralfate	23	18
Acyclovir	Acyclovir	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	22	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	22	suppressed
Tasigna	Nilotinib Hcl	22	suppressed
Ibrance	Palbociclib	21	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Calcitriol	Calcitriol	20	suppressed
Labetalol Hcl	Labetalol Hcl	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	19	12
Sprycel	Dasatinib	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Fentanyl	Fentanyl	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Methylprednisolone	Methylprednisolone	18	15
Bexarotene	Bexarotene	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	16	suppressed
Carisoprodol	Carisoprodol	16	suppressed
Gazyva	Obinutuzumab	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	16	suppressed
Oxbryta	Voxelotor	16	suppressed
Testosterone	Testosterone	16	suppressed
Zarxio	Filgrastim-Sndz	16	suppressed
Alendronate Sodium	Alendronate Sodium	15	suppressed
Diclofenac Potassium	Diclofenac Potassium	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Lonsurf	Trifluridine/Tipiracil Hcl	14	suppressed
Losartan Potassium	Losartan Potassium	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Constulose	Lactulose	13	11
Enoxaparin Sodium	Enoxaparin Sodium	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Nubeqa	Darolutamide	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Veozah	Fezolinetant	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Methadone Hcl	Methadone Hcl	12	suppressed
Perjeta	Pertuzumab	12	suppressed
Erlotinib Hcl	Erlotinib Hcl	11	suppressed
Everolimus	Everolimus	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Imatinib Mesylate	Imatinib Mesylate	11	suppressed
Lactulose	Lactulose	11	suppressed
Potassium Citrate Er	Potassium Citrate	11	suppressed
Roflumilast	Roflumilast	11	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	11	suppressed
Somatuline Depot	Lanreotide Acetate	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$13.56 · 1 records	PFIZER INC.	ADCETRIS, ELREXFIO	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error